144 related articles for article (PubMed ID: 37368083)
1. Round-robin testing for LMO2 and MYC as immunohistochemical markers to screen MYC rearrangements in aggressive large B-cell lymphoma.
Papaleo N; Climent F; Tapia G; Luizaga L; Azcarate J; Bosch-Schips J; Muñoz-Marmol AM; Salido M; Lome-Maldonado C; Vazquez I; Colomo L
Virchows Arch; 2023 Jun; ():. PubMed ID: 37368083
[TBL] [Abstract][Full Text] [Related]
2. Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas.
Vazquez I; Papaleo N; Garcia E; Salido M; Salar A; Hernandez S; Calvo X; Colomo L
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260556
[TBL] [Abstract][Full Text] [Related]
3. Lack of expression of LMO2 clone SP51 identifies MYC rearrangements in aggressive large B-cell lymphomas.
Vazquez I; Papaleo N; Lop J; Puiggros A; Sanchez-Gonzalez B; Diez-Feijoo R; Gimeno E; Andrade-Campos M; Salar A; Espinet B; Salido M; Tapia G; Carreras J; Ferrer A; Arenillas L; Calvo X; Colomo L
Virchows Arch; 2021 Dec; 479(6):1073-1078. PubMed ID: 33811533
[TBL] [Abstract][Full Text] [Related]
4. LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.
Colomo L; Vazquez I; Papaleo N; Espinet B; Ferrer A; Franco C; Comerma L; Hernandez S; Calvo X; Salar A; Climent F; Mate JL; Forcada P; Mozos A; Nonell L; Martinez A; Carrio A; Costa D; Dlouhy I; Salaverria I; Martin-Subero JI; Lopez-Guillermo A; Valera A; Campo E;
Am J Surg Pathol; 2017 Jul; 41(7):877-886. PubMed ID: 28288039
[TBL] [Abstract][Full Text] [Related]
5. Screening Strategy for Detecting Double-Hit Lymphoma in a Resource-Limited Setting.
Thirunavukkarasu B; Bal A; Prakash G; Malhotra P; Singh H; Das A
Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):49-55. PubMed ID: 34456240
[TBL] [Abstract][Full Text] [Related]
6. High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs.
Marino FZ; Aquino G; Brunelli M; Scognamiglio G; Pedron S; Ronchi A; Cozzolino I; Sparano L; Botti G; Panico L; De Chiara A; Franco R;
Virchows Arch; 2021 Sep; 479(3):565-573. PubMed ID: 33768318
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
8. Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
Miyaoka M; Kikuti YY; Carreras J; Ikoma H; Hiraiwa S; Ichiki A; Kojima M; Ando K; Yokose T; Sakai R; Hoshikawa M; Tomita N; Miura I; Takata K; Yoshino T; Takizawa J; Bea S; Campo E; Nakamura N
Mod Pathol; 2018 Feb; 31(2):313-326. PubMed ID: 28984304
[TBL] [Abstract][Full Text] [Related]
9. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: Biopsy analysis of 70 cases from the Slovak Lymphoma Registry.
Lešková K; Szépe P; Balhárek T; Barthová M; Janáková Ľ; Farkašová A; Plank L
Neoplasma; 2022 Jul; 69(4):957-964. PubMed ID: 35652622
[TBL] [Abstract][Full Text] [Related]
10. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of HGAL and LMO2 immunohistochemistry in the identification of follicular lymphomas of the non-gastric gastrointestinal tract.
Chapman-Fredricks J; Younes SF; Fan YS; Sandoval-Sus JD; Natkunam Y; Lossos IS
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):200-4. PubMed ID: 22914613
[TBL] [Abstract][Full Text] [Related]
12. Role of immunohistochemistry in the era of genetic testing in MYC-positive aggressive B-cell lymphomas: a study of 209 cases.
Agarwal R; Lade S; Liew D; Rogers TM; Byrne D; Feleppa F; Juneja S; Westerman DA
J Clin Pathol; 2016 Mar; 69(3):266-70. PubMed ID: 26307073
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
14. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration.
Rymkiewicz G; Grygalewicz B; Chechlinska M; Blachnio K; Bystydzienski Z; Romejko-Jarosinska J; Woroniecka R; Zajdel M; Domanska-Czyz K; Martin-Garcia D; Nadeu F; Swoboda P; Rygier J; Pienkowska-Grela B; Siwicki JK; Prochorec-Sobieszek M; Salaverria I; Siebert R; Walewski J
Mod Pathol; 2018 May; 31(5):732-743. PubMed ID: 29327714
[TBL] [Abstract][Full Text] [Related]
16. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.
Horn H; Ziepert M; Wartenberg M; Staiger AM; Barth TF; Bernd HW; Feller AC; Klapper W; Stuhlmann-Laeisz C; Hummel M; Stein H; Lenze D; Hartmann S; Hansmann ML; Möller P; Cogliatti S; Pfreundschuh M; Trümper L; Loeffler M; Glass B; Schmitz N; Ott G; Rosenwald A;
Leukemia; 2015 Jul; 29(7):1564-70. PubMed ID: 25687653
[TBL] [Abstract][Full Text] [Related]
17. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications.
Baptista MJ; Tapia G; Muñoz-Marmol AM; Muncunill J; Garcia O; Montoto S; Gribben JG; Calaminici M; Martinez A; Veloza L; Martínez-Trillos A; Aldamiz T; Menarguez J; Terol MJ; Ferrandez A; Alcoceba M; Briones J; González-Barca E; Climent F; Muntañola A; Moraleda JM; Provencio M; Abrisqueta P; Abella E; Colomo L; García-Ballesteros C; Garcia-Caro M; Sancho JM; Ribera JM; Mate JL; Navarro JT
Histopathology; 2022 Dec; 81(6):826-840. PubMed ID: 36109172
[TBL] [Abstract][Full Text] [Related]
18. A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.
Bosch M; Akhter A; Chen BE; Mansoor A; Lebrun D; Good D; Crump M; Shepherd L; Scott DW; Stewart DA
Haematologica; 2018 Feb; 103(2):288-296. PubMed ID: 29097500
[TBL] [Abstract][Full Text] [Related]
19. Bright CD38 Expression by Flow Cytometric Analysis Is a Biomarker for Double/Triple Hit Lymphomas with a Moderate Sensitivity and High Specificity.
Alsuwaidan A; Pirruccello E; Jaso J; Koduru P; Garcia R; Krueger J; Doucet M; Chaudhry R; Fuda F; Chen W
Cytometry B Clin Cytom; 2019 Sep; 96(5):368-374. PubMed ID: 30734478
[TBL] [Abstract][Full Text] [Related]
20. Inferior survival in high-grade B-cell lymphoma with
McPhail ED; Maurer MJ; Macon WR; Feldman AL; Kurtin PJ; Ketterling RP; Vaidya R; Cerhan JR; Ansell SM; Porrata LF; Nowakowski GS; Witzig TE; Habermann TM
Haematologica; 2018 Nov; 103(11):1899-1907. PubMed ID: 29903764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
